

# On the mechanism of biosynthesis of leukotrienes and related compounds

Alexander Panossian<sup>+</sup>, Mats Hamberg and Bengt Samuelsson\*

Department of Chemistry, Karolinska Institutet, S-104 01 Stockholm, Sweden and <sup>+</sup>Inst. of Fine Organic Chemistry, Armenian Academy of Sciences, Yerevan, USSR

Received 8 November 1982

[10D-<sup>3</sup>H; 3-<sup>14</sup>C]- and [10L-<sup>3</sup>H; 3-<sup>14</sup>C]arachidonic acids were incubated with human polymorphonuclear leukocytes and with human platelets. Leukotriene B<sub>4</sub> and 5(S),12(S)-dihydroxy-6*trans*,8*cis*,10*trans*,14*cis*-eicosatetraenoic acid (5,12-DHETE) were isolated and the <sup>3</sup>H/<sup>14</sup>C ratios determined. It could be concluded that the 10D (*pro-R*)-hydrogen is eliminated in the conversion of 5(S)-hydroperoxy-6*trans*,8*cis*,11*cis*,14*cis*-eicosatetraenoic acid into leukotriene A<sub>4</sub> whereas in the conversion of arachidonic acid into 5,12-DHETE the 10L (*pro-S*)-hydrogen is lost. Incubation of the doubly labeled arachidonic acids with human platelets confirmed and extended previous data on the stereochemistry of the hydrogen removal from C-10 during the conversion into 12(S)-hydroperoxy-5*cis*,8*cis*,10*trans*,14*cis*-eicosatetraenoic acid, i.e., the 10L (*pro-S*)-hydrogen is eliminated and the 10D (*pro-R*)-hydrogen retained.

<i>Leukotriene A<sub>4</sub></i>	<i>5(S),12(S)-dihydroxy-6,8,10,14-eicosatetraenoic acid</i>	
<i>12(S)-hydroperoxy-5,8,10,14-eicosatetraenoic acid</i>	<i>Stereospecific hydrogen removal</i>	<i>Isotope effect</i>

## 1. INTRODUCTION

Two reactions are involved in the formation of leukotriene A<sub>4</sub> (LTA<sub>4</sub>) from arachidonic acid:

- (1) A lipoxygenase reaction by which arachidonic acid is transformed into 5(S)-hydroperoxy-6*trans*,8*cis*,11*cis*,14*cis*-eicosatetraenoic acid (5-HPETE) [1];
- (2) A dehydrase reaction in which the hydroperoxide is cyclized into 5(S)-*trans*-5,6-oxido-7*trans*,9*trans*,11*cis*,14*cis*-eicosatetraenoic acid (LTA<sub>4</sub>) [2].

Several compounds are formed by further transformation of LTA<sub>4</sub>; i.e., leukotriene B<sub>4</sub> (LTB<sub>4</sub>, 5(S),12(R)-dihydroxy-6*cis*,8*trans*,10*trans*,14*cis*-eicosatetraenoic acid), 5(S),12(R)-dihydroxy-6*trans*,8*trans*,10*trans*,14*cis*-eicosatetraenoic acid, and 5(S),12(S)-dihydroxy-6*trans*,8*trans*,10*trans*,14*cis*-eicosatetraenoic acid as well as the amino acid containing leukotrienes LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub> [2]. Human polymorphonuclear leukocytes have also

been found to produce 5(S),12(S)-dihydroxy-6*trans*,8*cis*,10*trans*,14*cis*-eicosatetraenoic acid (5,12-DHETE) [3,4]. This dihydroxy acid, although isomeric with LTB<sub>4</sub>, is not formed from LTA<sub>4</sub> but by double dioxygenation of arachidonic acid. The compound is therefore not included in the leukotriene family.

This work is concerned with the stereochemistry of the hydrogen removal from C-10 of arachidonic acid during the biosynthesis of leukotrienes and of 5,12-DHETE.

## 2. MATERIALS AND METHODS

Human polymorphonuclear leukocytes (HPMNL) were isolated from leukocyte concentrates obtained from blood as in [5]. [10L-<sup>3</sup>H; 3-<sup>14</sup>C]arachidonic acid was prepared as in [6] (see fig. 1). [10D-<sup>3</sup>H; 3-<sup>14</sup>C]arachidonic acid was obtained in a similar way except for the use of (+)-α-phenylethylamine for preparation of 3L-hydroxytridecanoic acid (cf. [7]; see fig. 1). The yield of labeled arachidonic acids from labeled

\* To whom correspondence should be addressed




Fig. 1. Reactions used to prepare [10D- $^3\text{H}$ ; 3- $^{14}\text{C}$ ]- and [10L- $^3\text{H}$ ; 3- $^{14}\text{C}$ ]arachidonic acids; 'Ts', *p*-toluenesulfonyl.

stearic acids following incubation with the fungus, *Saprolegnia parasitica*, was 0.5–20%.

The cell preparation ( $\sim 100 \times 10^6$  HPMNL/ml; contaminated with platelets) was stirred for 10 min at  $37^\circ\text{C}$  in the presence of ionophore A 23187 (5  $\mu\text{M}$ ) and the doubly labeled arachidonic acids (150  $\mu\text{M}$ , 0.05–0.5  $\mu\text{Ci}$  of  $^{14}\text{C}$ ). The incubations were stopped by the addition of 1.5 vol. of methanol and the diethyl ether extracts were subjected to silicic acid chromatography (column, 1 g of silicic acid CC-4 obtained from Mallinckrodt). Elution was performed stepwise with diethyl ether–hexane 1:9 (v/v), diethyl ether–hexane 4:6 (v/v), and ethyl acetate. The material eluted with ethyl acetate was subjected to reversed-phase and straight-phase high-performance liquid chromatography essentially as in [3]. Here, the methyl esters of 5,12-DHETE and  $\text{LTB}_4$  were identified and collected.

The doubly-labeled arachidonic acids were also incubated with suspensions of human platelets [6]. The products, i.e., 12-HETE, 12-HHT and thromboxane  $\text{B}_2$  ( $\text{TXB}_2$ ) [8] were isolated in form of their methyl esters by thin-layer chromatography.

$^3\text{H}/^{14}\text{C}$  ratios of the incubated arachidonic acids as well as of the products formed in leukocytes and platelets were determined with a Packard TriCarb model 3375 liquid scintillation spectrometer using Instagel<sup>®</sup> as scintillation fluor.

Table 1

Relative retention of  $^3\text{H}$  in  $\text{LTB}_4$  and 5,12-DHETE observed upon incubation of [10D- $^3\text{H}$ ; 3- $^{14}\text{C}$ ]- and [10L- $^3\text{H}$ ; 3- $^{14}\text{C}$ ]arachidonic acids with HPMNL

20:4 incubated $^3\text{H}/^{14}\text{C}$ (%)	$\text{LTB}_4$ $^3\text{H}/^{14}\text{C}$ (%)	5,12-DHETE $^3\text{H}/^{14}\text{C}$ (%)
[10D- $^3\text{H}$ ; 3- $^{14}\text{C}$ ]20:4		
100	22	128
100	27	149
100	—	139
[10L- $^3\text{H}$ ; 3- $^{14}\text{C}$ ]20:4		
100	98	9

### 3. RESULTS AND DISCUSSION

#### 3.1. Incubation with leukocytes

[10D- $^3\text{H}$ ; 3- $^{14}\text{C}$ ]- and [10L- $^3\text{H}$ ; 3- $^{14}\text{C}$ ]arachidonic acids were incubated with suspensions of HPMNL as above.  $^3\text{H}/^{14}\text{C}$  ratios of 5,12-DHETE and  $\text{LTB}_4$  relative to that of the corresponding precursor acid are given in table 1.

As seen, during the conversion of the 10D-tritio arachidonic acid into  $\text{LTB}_4$  tritium was largely lost. On the other hand, there was no loss of  $^3\text{H}$  during the formation of 5,12-DHETE. Instead a certain enrichment of tritium was observed (table 1).  $\text{LTB}_4$  formed from the 10L-tritio arachidonic acid retained the  $^3\text{H}$  label whereas 5,12-DHETE lost most of the tritium.

These data show that the 10D (*pro-R*)-hydrogen is lost during the formation of  $\text{LTA}_4$  from 5-HPETE whereas the 10L (*pro-S*)-hydrogen is lost upon formation of 5,12-DHETE from arachidonic acid. The enrichment of tritium in 5,12-DHETE observed when formed from [10D- $^3\text{H}$ ; 3- $^{14}\text{C}$ ]arachidonic acid suggests the presence of isotope effects in the conversions of the 10D-tritio arachidonic acid. A likely explanation for the enrichment involves the presence of an isotope effect in the conversion of [10D- $^3\text{H}$ ; 3- $^{14}\text{C}$ ]5-HPETE into [3- $^{14}\text{C}$ ]LTA $_4$ . 5-HPETE remaining unconverted will thus be enriched with respect to tritium. Dioxygenation at C-12 does not involve elimination of the 10D-tritium ([6]; table 2). Therefore the resulting [10- $^3\text{H}$ ; 3- $^{14}\text{C}$ ]5,12-DHETE should be enriched with tritium. In order to study this question

Table 2

Relative retention of  $^3\text{H}$  in 12-HETE, 12-HHT and  $\text{TXB}_2$  observed following incubation of  $[10\text{D-}^3\text{H}; 3\text{-}^{14}\text{C}]$ - and  $[10\text{L-}^3\text{H}; 3\text{-}^{14}\text{C}]$ arachidonic acids with human platelets

20:4 incubated $^3\text{H}/^{14}\text{C}$ (%)	12-HETE $^3\text{H}/^{14}\text{C}$ (%)	12-HHT $^3\text{H}/^{14}\text{C}$ (%)	$\text{TXB}_2$ $^3\text{H}/^{14}\text{C}$ (%)
$[10\text{D-}^3\text{H}; 3\text{-}^{14}\text{C}]20:4$			
100	95	2	98
100 <sup>a</sup>	96	—	—
$[10\text{L-}^3\text{H}; 3\text{-}^{14}\text{C}]20:4$			
100 <sup>a</sup>	9	—	—

<sup>a</sup>Indomethacin (10  $\mu\text{g/ml}$ ) was added




Fig. 2. Scheme of transformation of arachidonic acid into  $\text{LTA}_4$  and 5,12-DHETE; (\*) 10D (*pro-R*)-hydrogen of arachidonic acid and 5-HPETE.

in more detail, a separate experiment was carried out in which 5,12-DHETE, as well as 5-HETE were isolated and analysed following incubation of  $[10\text{D-}^3\text{H}; 3\text{-}^{14}\text{C}]$ arachidonic acid. In agreement with the interpretation discussed above (fig. 2) 5,12-DHETE as well as 5-HETE (reduction product of 5-HPETE) were found to be enriched with respect to tritium (130% and 167% relative to pre-

cursor, respectively). It thus appears that 5,12-DHETE may be formed by the sequence arachidonic acid  $\rightarrow$  5-HPETE  $\rightarrow$  5,12-DHETE (fig. 2). However, these data do not exclude the possibility of simultaneous formation of 5,12-DHETE by the alternate sequence of reactions; i.e., arachidonic acid  $\rightarrow$  12-HPETE  $\rightarrow$  5,12-DHETE.

### 3.2. Incubation with platelets

$[10\text{D-}^3\text{H}; 3\text{-}^{14}\text{C}]$ - and  $[10\text{L-}^3\text{H}; 3\text{-}^{14}\text{C}]$ arachidonic acids were incubated with suspensions of human platelets as in [6,8]. Table 2 gives the relative retentions of  $^3\text{H}$  in the products.

It has been found that tritium is lost during the conversion of  $[10\text{L-}^3\text{H}; 3\text{-}^{14}\text{C}]$ arachidonic acid into 12-HETE [6]. This result was confirmed here. Furthermore, the 10D-tritio arachidonic acid was found to retain its  $^3\text{H}$  label upon conversion into 12-HETE (table 2). Also, as would be expected [8],  $\text{TXB}_2$  retained the  $^3\text{H}$  label when formed from  $[10\text{D-}^3\text{H}; 3\text{-}^{14}\text{C}]$ arachidonic acid, whereas 12-HHT was essentially devoid of  $^3\text{H}$  (table 2).

### ACKNOWLEDGEMENTS

We wish to thank Mrs G. Hamberg for excellent technical assistance. This work was supported by grants from the Swedish Medical Research Council (projects no. 03X-217 and 03X-05170).

### REFERENCES

- [1] Borgeat, P., Hamberg, M. and Samuelsson, B. (1976) *J. Biol. Chem.* 251, 7816–7820; see also correction (1977) *J. Biol. Chem.* 252, 8772.
- [2] Samuelsson, B. (1982) in: *Leukotrienes and other lipoxygenase products* (Samuelsson, B. and Paoletti, R., eds) *Advances in Prostaglandin, Thromboxane and Leukotriene Research*, vol. 9, pp. 1–17, Raven, New York.
- [3] Lindgren, J.-Å., Hansson, G. and Samuelsson, B. (1981) *FEBS Lett.* 128, 329–335.
- [4] Borgeat, P., Picard, S., Vallerand, P. and Sirois, P. (1981) *Prostaglandins Med.* 6, 557–570.
- [5] Bøyum, A. (1976) *Scand. J. Immunol. suppl.* 5, 5, 9–15.
- [6] Hamberg, M. and Hamberg, G. (1980) *Biochem. Biophys. Res. Commun.* 95, 1090–1097.
- [7] Stoffel, W., Caesar, H. and Ditzer, R. (1964) *Hoppe-Seyler's Zeitsch. f. physiol. Chemie* 339, 182–193.
- [8] Hamberg, M. and Samuelsson, B. (1974) *Proc. Natl. Acad. Sci. USA* 71, 3400–3404.